RT Journal Article
SR Electronic
T1 From elimination to suppression: genomic epidemiology of a large Delta SARS-CoV-2 outbreak in Aotearoa New Zealand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.04.22273376
DO 10.1101/2022.04.04.22273376
A1 Jelley, Lauren
A1 Douglas, Jordan
A1 Ren, Xiaoyun
A1 Winter, David
A1 McNeill, Andrea
A1 Huang, Sue
A1 French, Nigel
A1 Welch, David
A1 Hadfield, James
A1 de Ligt, Joep
A1 Geoghegan, Jemma L
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2022.04.04.22273376.abstract
AB New Zealand’s COVID-19 elimination strategy heavily relied on the use of genomics to inform contact tracing, linking cases to the border and to clusters during community outbreaks. In August 2021, New Zealand entered its second nationwide lockdown after the detection of a single community case with no immediately apparent epidemiological link to the border. This incursion resulted in the largest outbreak seen in New Zealand caused by the Delta Variant of Concern. Here we generated 3806 high quality SARS-CoV-2 genomes from cases reported in New Zealand between 17 August and 1 December 2021, representing 43% of reported cases. We detected wide geographical spread coupled with undetected community transmission, characterised by the apparent extinction and reappearance of genomically linked clusters. We also identified the emergence, and near replacement, of genomes possessing a 10-nucleotide frameshift deletion that caused the likely truncation of accessory protein ORF7a. By early October, New Zealand moved from elimination to suppression and the role of genomics changed markedly from being used to track and trace, towards population-level surveillance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at https://www.gisaid.org/. Nasopharyngeal samples that had positive results for SARS-CoV-2 by real-time reverse transcription PCR were obtained from medical diagnostic laboratories located throughout New Zealand. Under contract for the New Zealand Ministry of Health, we (the Institute of Environmental Science and Research) has approval to conduct genomic sequencing and phylogenetic analysis for surveillance of notifiable diseases and permission from the Ministry to publish these data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available via GISAID https://www.gisaid.org/